Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It can manifest as mild to severe flu-like and non-flu-like symptoms and signs, which are associated with immune dysfunction and increased mortality. The findings from COVID-19 patients imply a link between immune system abnormalities such as impaired T-cell responses or cytokine imbalances and increased risk for worse clinical outcomes, which has not been fully understood. Owing to the regulatory role of inhibitory immune checkpoints during COVID-19 infection, this review summarizes the available studies concerning the TIM3 as a relatively less characterized immune checkpoint in COVID-19 patients.

Department of Cell Biology Faculty of Science Charles University Prague Czech Republic

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Prague Czech Republic

See more in PubMed

Hu B., et al. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19(3):141–154. PubMed PMC

Gibson P.G., Qin L., Puah S.H. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. The Medical journal of Australia. 2020;213(2):54–56.e1. PubMed PMC

Elezkurtaj S., et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci. Rep. 2021;11(1):4263. PubMed PMC

Diao B., et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Front. Immunol. 2020;11:827. PubMed PMC

He X., Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–669. PubMed PMC

Schönrich G., Raftery M.J. The PD-1/PD-L1 Axis and virus infections: a delicate balance. Front. Cell. Infect. Microbiol. 2019;9:207. PubMed PMC

Marin-Acevedo J.A., Kimbrough E.O., Lou Y. Next generation of immune checkpoint inhibitors and beyond. J. Hematol. Oncol. 2021;14(1):45. PubMed PMC

Leavy O. TIM3: dual role in immunity. Nat. Rev. Immunol. 2008;8(1) 4-4.

Carbonell R., et al. The role of biomarkers in influenza and COVID-19 community-acquired pneumonia in adults. Antibiotics. 2023;12 doi: 10.3390/antibiotics12010161. PubMed DOI PMC

Greisen S.R., Aspari M., Deleuran B. Co-inhibitory molecules - their role in health and autoimmunity; highlighted by immune related adverse events. Front. Immunol. 2022;13 PubMed PMC

Barnova M., et al. Inhibitory immune checkpoint molecules and exhaustion of T cells in COVID-19. Physiol. Res. 2021;70(S2):S227–s247. PubMed PMC

Jones N.L. The tim family: new players in the Th1/Th2 paradigm. Pediatr. Res. 2002;52(1) 1-1.

Wolf Y., Anderson A.C., Kuchroo V.K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 2020;20(3):173–185. PubMed PMC

van de Weyer P.S., et al. A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochemical and biophysical research communications. 2006;351(2):571–576. PubMed

Chihara N., et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018;558(7710):454–459. PubMed PMC

Möller-Hackbarth K., et al. A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3) J. Biol. Chem. 2013;288(48):34529–34544. PubMed PMC

Hansen J.A., et al. A novel soluble form of Tim-3 associated with severe graft-versus-host disease. Biol. Blood Marrow Transplant. 2013;19(9):1323–1330. PubMed PMC

Clayton K.L., et al. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression. J. Virol. 2015;89(7):3723–3736. PubMed PMC

Polprasert C., et al. Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma. Blood Advances. 2019;3(4):588–595. PubMed PMC

Gayden T., et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat. Genet. 2018;50(12):1650–1657. PubMed

Fang H., et al. Association between TIM-3 polymorphisms and cancer risk: a meta-analysis. Ann. Transl. Med. 2019;7(20) 550-550. PubMed PMC

Razi B., et al. TIM family gene polymorphism and susceptibility to rheumatoid arthritis: systematic review and meta-analysis. PLoS One. 2019;14(2) PubMed PMC

Fourcade J., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010;207(10):2175–2186. PubMed PMC

Sakhdari A., et al. Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLoS One. 2012;7(7) PubMed PMC

Grabmeier-Pfistershammer K., et al. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade. Clin. Immunol. 2017;183:167–173. PubMed

Morou A., Palmer B.E., Kaufmann D.E. Distinctive features of CD4+ T cell dysfunction in chronic viral infections. Curr. Opin. HIV AIDS. 2014;9(5) PubMed PMC

Golden-Mason L., et al. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 2007;81(17):9249–9258. PubMed PMC

Merani S., Chen W., Elahi S. The bitter side of sweet: the role of Galectin-9 in immunopathogenesis of viral infections. Rev. Med. Virol. 2015;25(3):175–186. PubMed

Shi Q., et al. Negative regulation of RIG-I by tim-3 promotes H1N1 infection. Immunol. Invest. 2022:1–19. PubMed

Shahbaz S., et al. Immunological responses in SARS-CoV-2 and HIV co-infection versus SARS-CoV-2 mono-infection: case report of the interplay between SARS-CoV-2 and HIV. Allergy Asthma Clin. Immunol. 2023;19(1):91. PubMed PMC

Autissier P., et al. Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans. Cytometry. 2010;77(5):410–419. PubMed PMC

Yuan Y., et al. Peripheral blood mononuclear cell biomarkers predict response to immune checkpoint inhibitor therapy in metastatic breast cancer. Ann. Oncol. 2018;29:viii94.

Wang F., et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10) PubMed PMC

Varchetta S., et al. Unique immunological profile in patients with COVID-19. Cell. Mol. Immunol. 2021;18(3):604–612. PubMed PMC

Modabber Z., et al. TIM-3 as a potential exhaustion marker in CD4(+) T cells of COVID-19 patients. Immun Inflamm Dis. 2021;9(4):1707–1715. PubMed PMC

Shahbazi M., et al. Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients. Microb. Pathog. 2021;153 PubMed PMC

Martín-Quirós A., et al. Potential role of the galectin-9/TIM-3 Axis in the disparate progression of SARS-CoV-2 in a married couple: a case report. Biomed. Hub. 2021;6(1):48–58. PubMed PMC

Yang J., et al. Increased expression of tim-3 is associated with depletion of NKT cells in SARS-CoV-2 infection. Front. Immunol. 2022;13 PubMed PMC

Coulon P.-G., et al. High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4+ and CD8+ memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients. Front. Immunol. 2024;15 PubMed PMC

Wang F., et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10) PubMed PMC

Bobcakova A., et al. Immune profile in patients with COVID-19: lymphocytes exhaustion markers in relationship to clinical outcome. Front. Cell. Infect. Microbiol. 2021;11 PubMed PMC

Phetsouphanh C., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23(2):210–216. PubMed

Hou H., et al. Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection. J. Allergy Clin. Immunol. 2021;148(6):1481–1492.e2. PubMed PMC

Vazquez-Alejo E., et al. SARS-CoV2 infection during pregnancy causes persistent immune abnormalities in women without affecting the newborns. Front. Immunol. 2022;13 PubMed PMC

Wu H., et al. Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation. Nat. Commun. 2022;13(1):269. PubMed PMC

Cazzato G., et al. HMGB1-TIM3-HO1: a new pathway of inflammation in skin of SARS-CoV-2 patients? A retrospective pilot study. Biomolecules. 2021;11(8):1219. PubMed PMC

Chen P.K., et al. Interleukin-18 is a potential biomarker to discriminate active adult-onset still's disease from COVID-19. Front. Immunol. 2021;12 PubMed PMC

Trøseid M., et al. Persistent T-cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID-19: results from two Norwegian cohort studies. J. Intern. Med. 2022;292(5):816–828. PubMed PMC

Chavez-Galan L., et al. Circulating levels of PD-L1, TIM-3 and MMP-7 are promising biomarkers to differentiate COVID-19 patients that require invasive mechanical ventilation. Biomolecules. 2022;12(3):445. PubMed PMC

Kong Y., et al. Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduct Target Ther. 2020;5(1):192. PubMed PMC

Avendaño-Ortiz J., et al. The immune checkpoints storm in COVID-19: role as severity markers at emergency department admission. Clin. Transl. Med. 2021;11(10):e573. PubMed PMC

Ueland T., et al. Elevated plasma sTIM-3 levels in patients with severe COVID-19. J. Allergy Clin. Immunol. 2021;147(1):92–98. PubMed PMC

Hsieh M.C., et al. Elevated serum levels of T-cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic inflammation following COVID-19 vaccination. J. Chin. Med. Assoc. 2023;86(9):818–825. PubMed

Herrmann M., et al. Analysis of Co-inhibitory receptor expression in COVID-19 infection compared to acute plasmodium falciparum malaria: LAG-3 and TIM-3 correlate with T cell activation and course of disease. Front. Immunol. 2020;11:1870. PubMed PMC

Yao Y., et al. A-lactose improves the survival of septic mice by blockade of TIM-3 signaling to prevent NKT cell apoptosis and attenuate cytokine storm. Shock. 2017;47(3):337–345. PubMed

Vazquez-Alejo E., et al. SARS-CoV2 infection during pregnancy causes persistent immune abnormalities in women without affecting the newborns. Front. Immunol. 2022;13 PubMed PMC

Chen R., et al. HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon. 2020;6(12) PubMed PMC

Avery L., et al. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. Proc. Natl. Acad. Sci. USA. 2018;115(10):2455–2460. PubMed PMC

Smith C.M., et al. Phosphatidylserine binding directly regulates TIM-3 function. Biochem. J. 2021;478(17):3331–3349. PubMed PMC

Lee J., et al. TIM polymorphisms--genetics and function. Genes Immun. 2011;12(8):595–604. PubMed PMC

Murtaza A., et al. Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody. European Journal of Cancer. 2016;69

Saresella M., et al. A role for the TIM-3/GAL-9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis. Faseb j. 2014;28(11):5000–5009. PubMed

Zhu C., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005;6(12):1245–1252. PubMed

Dapat I.C., et al. Secretion of galectin-9 as a DAMP during dengue virus infection in THP-1 cells. Int. J. Mol. Sci. 2017;18(8) PubMed PMC

Bozorgmehr N., et al. Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 infection. mBio. 2021;12(3) PubMed PMC

Du L., et al. Human galectin-9 potently enhances SARS-CoV-2 replication and inflammation in airway epithelial cells. J. Mol. Cell Biol. 2023;15(4):mjad030. doi: 10.1093/jmcb/mjad030. PubMed DOI PMC

DeKruyff R.H., et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 2010;184(4):1918–1930. PubMed PMC

Zhao D., et al. Frontline Science: tim-3-mediated dysfunctional engulfment of apoptotic cells in SLE. J. Leukoc. Biol. 2017;102(6):1313–1322. PubMed

Nakayama M., et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113(16):3821–3830. PubMed

Tan S., et al. Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling. Cancer Res. 2020;80(5):1130–1142. PubMed

Althaus K., et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021;137(8):1061–1071. PubMed PMC

Curtin J.F., et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009;6(1) PubMed PMC

Tesniere A., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482–491. PubMed

de Mingo Pulido A., et al. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021;54(6):1154–1167. e7. PubMed PMC

Wyganowska-Swiatkowska M., et al. Influence of herbal medicines on HMGB1 release, SARS-CoV-2 viral attachment, acute respiratory failure, and sepsis. A literature review. Int. J. Mol. Sci. 2020;21 doi: 10.3390/ijms21134639. PubMed DOI PMC

Zou H., et al. Destruction in maternal-fetal interface of URSA patients via the increase of the HMGB1-RAGE/TLR2/TLR4-NF-κB signaling pathway. Life Sci. 2020;250 PubMed

Chen L., et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell. Mol. Immunol. 2020;17(9):992–994. PubMed PMC

Chen G., et al. Pathogenic role of HMGB1 in SARS? Med. Hypotheses. 2004;63(4):691–695. PubMed PMC

Gray-Owen S.D., Blumberg R.S. CEACAM1: contact-dependent control of immunity. Nat. Rev. Immunol. 2006;6(6):433–446. PubMed

Huang Y.H., et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386–390. PubMed PMC

Khairnar V., et al. CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. Nat. Commun. 2018;9(1):2561. PubMed PMC

Sabatos-Peyton C.A., et al. Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. OncoImmunology. 2018;7(2) PubMed PMC

Klaile E., et al. Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their expression can be modulated in bronchial epithelial cells by non-typable Haemophilus influenzae, Moraxella catarrhalis, TLR3, and type I and II interferons. Respir. Res. 2013;14(1):85. PubMed PMC

Liao M., et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844. PubMed

Huang R., et al. The predicting roles of carcinoembryonic antigen and its underlying mechanism in the progression of coronavirus disease 2019. Crit. Care. 2021;25(1):234. PubMed PMC

Saheb Sharif-Askari N., et al. Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection. Molecular Therapy - Methods & Clinical Development. 2021;20:109–121. PubMed PMC

Bohan D., et al. Phosphatidylserine receptors enhance SARS-CoV-2 infection. PLoS Pathog. 2021;17(11) PubMed PMC

Ferris R.L., Lu B., Kane L.P. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J. Immunol. 2014;193(4):1525–1530. PubMed PMC

Yuan C., et al. The role of cell death in SARS-CoV-2 infection. Signal Transduct. Targeted Ther. 2023;8(1):357. PubMed PMC

Alrajhi N.N. Post-COVID-19 pulmonary fibrosis: an ongoing concern. Ann. Thorac. Med. 2023;18(4):173–181. PubMed PMC

Hotchkiss R.S., et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med. 2019;45(10):1360–1371. PubMed PMC

Lee L.Y., et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926. PubMed PMC

Yang K., et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904–913. PubMed PMC

Mehta V., et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital system. Cancer Discov. 2020;10(7):935–941. PubMed PMC

Robilotti E.V., et al. Determinants of COVID-19 disease severity in patients with cancer. Nat. Med. 2020;26(8):1218–1223. PubMed PMC

He Y., et al. TIM-3, a promising target for cancer immunotherapy. OncoTargets Ther. 2018;11:7005–7009. PubMed PMC

Luo J., et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 2020;10(8):1121–1128. PubMed PMC